Molecules inducing specific cyclin-dependent kinase degradation and their possible use in cancer therapy

Area of Science:

• Molecular Biology
• Cell Biology
• Pharmacology

Background:

• Cyclin-dependent kinases (CDKs) are crucial regulators of cell proliferation and transcription.
• Existing CDK inhibitors, including pan-CDK and selective CDK4/6 inhibitors, face limitations such as toxicity, low efficacy, and acquired resistance.
• Protein degraders represent a novel therapeutic strategy with the potential to overcome these limitations.

Purpose of the Study:

• To review the role of CDKs in cell cycle and transcription.
• To introduce representative CDK inhibitors and their limitations.
• To provide a detailed overview of four types of CDK degraders, including their mechanisms, current research, and future prospects.

Main Methods:

• Literature review of CDK functions and inhibitors.
• Analysis of the mechanisms of action for different types of CDK degraders.
• Summary of the research status and application prospects of CDK degraders.

Main Results:

• CDKs are essential for cell cycle progression and transcriptional regulation.
• Protein degraders offer enhanced selectivity and efficacy compared to traditional inhibitors.
• Four distinct classes of CDK degraders have emerged, each with unique mechanisms and therapeutic potential.

Conclusions:

• CDK degraders present a novel and potentially superior approach to targeting CDKs.
• Further development of CDK degraders could lead to more effective treatments for diseases involving aberrant cell proliferation.
• This review provides a comprehensive resource for understanding and developing novel CDK degraders.